养老院居民加巴喷丁类-袢利尿剂处方级联的预测因素
该回顾性队列纳入2016—2022年Medicare理赔数据与最小数据集链接的23,544例≥66岁、新起始加巴喷丁类且此前6个月无袢利尿剂使用、心衰或肾功能不全证据的养老院居民,994例(4.2%)在起始后中位36天发生袢利尿剂处方级联。高龄、慢性疼痛或纤维肌痛、糖尿病、使用保钾或噻嗪类利尿剂及合并用药≥15种与风险升高相关,较高 weekly 加巴喷丁剂量与13周内风险升高1.45倍相关,而阿尔茨海默病及相关痴呆及中重度认知障碍者风险较低。
要点
- 养老院新起始加巴喷丁类者约1/20在3个月内加用袢利尿剂,中位36天。
- 高龄、多种合并用药、合用其他利尿剂及较高加巴喷丁剂量与级联风险升高相关。
- 认知障碍者级联风险较低,仍应监测水肿并优先考虑减量或停药而非加利尿剂。
核心结论
- 养老院居民起始加巴喷丁类后约4.2%在90天内启动袢利尿剂,存在可干预的预测因素。
研究设计与样本
- 回顾性队列研究,链接2016—2022年Medicare理赔与Minimum Data Set评估,纳入23,544例≥66岁新起始加巴喷丁类且此前6个月无袢利尿剂、心衰或肾功能不全证据的养老院居民。
主要发现
- 994例(4.2%)发生处方级联,中位36天(IQR 15-61)。
- 年龄86-90岁aRR=1.60、≥91岁aRR=1.38;慢性疼痛或纤维肌痛aRR=1.16;糖尿病aRR=1.23。
- 使用保钾利尿剂aRR=1.53、噻嗪类aRR=1.27、≥15种独特药物aRR=1.18。
- 随访期较高 weekly 加巴喷丁剂量与13周内级联风险升高1.45倍相关。
- 阿尔茨海默病及相关痴呆aRR=0.79、中度认知障碍aRR=0.72、重度aRR=0.59,均低于认知完好者。
临床怎么用
- 养老院临床医生应在起始加巴喷丁类后早期监测水肿,并在加用袢利尿剂前考虑减量或停药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gabapentinoid-related peripheral edema may prompt loop diuretic prescribing. Nursing home (NH) residents may be especially prone to this prescribing cascade. We estimated the incidence and identified predictors of the gabapentinoid-loop diuretic prescribing cascade in NHs. METHODS: We conducted a retrospective cohort study using 2016-2022 Medicare claims linked with Minimum Data Set assessments. We identified residents aged ≥ 66 years who initiated gabapentinoids in NHs and who had no evidence of loop diuretic use, heart failure, or renal insufficiency during the prior 6 months. The outcome was loop diuretic initiation within 90 days of gabapentinoid initiation. Using multivariable Poisson regression models, we estimated adjusted risk ratios (aRR) with 95% robust confidence intervals to identify predictors. We used pooled logistic regression models to examine the relationship between time-varying gabapentinoid dose and loop diuretic initiation risk. RESULTS: Among 23,544 residents, 994 (4.2%) experienced a prescribing cascade at a median of 36 days (IQR 15-61) after gabapentinoid initiation. Risk was higher with age 86-90 years (aRR = 1.60) or ≥ 91 years (aRR = 1.38); a diagnosis of chronic pain or fibromyalgia (aRR = 1.16), or diabetes (aRR = 1.23); and receipt of potassium-sparing diuretics (aRR = 1.53), thiazide diuretics (aRR = 1.27), or 15 or more unique medications (aRR = 1.18). Higher (versus lower) weekly gabapentin dose during follow-up was associated with a 1.45 times higher prescribing cascade risk over 13 weeks. Those with Alzheimer's Disease and Related Dementias (aRR = 0.79), or moderate (aRR = 0.72) to severe cognitive impairment (aRR = 0.59) had a lower risk versus those with intact cognition. CONCLUSIONS: Approximately 1 in 20 NH residents who initiate gabapentinoids receives a loop diuretic within 3 months. Potentially modifiable predictors included existing polypharmacy and titrating gabapentinoid doses. NH clinicians should monitor for edema soon after gabapentinoid initiation and consider dose reductions or discontinuation before adding a loop diuretic.
引用
- Hayes KN, Belanger E, Oganisian A, et al. Predictors of a Gabapentinoid-Loop-Diuretic Prescribing Cascade in U.S. Nursing Home Residents. J Am Geriatr Soc. 2025. PMID: 41313166. doi:10.1111/jgs.70219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。